FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992603401> ?p ?o ?g. }

• W2992603401 abstract "Cutaneous squamous cell carcinoma (cSCC) is not uncommon in association with indolent malignancies that were treated with prior radiotherapy and after allogenic bone marrow transplantation. On the other hand, cutaneous T-cell lymphoma (CTCL) is a subtype of non-Hodgkin's lymphoma which is characterized by an indolent course, with relative refractoriness to conventional chemotherapies and radiotherapy, and occasionally referred for allogeneic hematopoietic cell transplantation (allo-HCT). Recently, the use of immune checkpoint inhibitors has gained attention in the treatment of both cutaneous squamous cell carcinoma and hematological malignancies. However, many patients with hematological malignancies eventually undergo allo-HCT, raising the concern of potential adverse events (graft versus host disease) due to manipulation of the immune system with use of checkpoint inhibitors.We describe a patient with relapsed refractory CTCL (Sézary Syndrome) who underwent allo-HCT with persistence of disease post-transplant. The patient additionally developed a progressively worsening lesion on the right shoulder which was biopsied and showed poorly differentiated carcinoma (cSCC). Pembrolizumab was started for the treatment of cSCC. After second cycle of treatment, the cSCC lesion responded dramatically to the use of immune checkpoint inhibitor. Also, the patient experienced significant resolution of pruritus and generalized erythema. During 24 months of follow up after initial treatment with checkpoint inhibition immunotherapy, the patient showed durable response of both cSCC and CTCL, as well as restoration of full donor chimerism, without obvious worsening of graft versus host disease (GVHD).This is the first case to our knowledge of rapid and durable response of both cSCC and CTCL to immune checkpoint inhibition after allo-HCT. Although this report highlights the potential for significant response to this class of medication, further studies are required to confirm the efficacy and safety of this approach in patients with CTCL after allo-HCT given the potential concern of GVHD." @default.
• W2992603401 created "2019-12-13" @default.
• W2992603401 creator A5003894390 @default.
• W2992603401 creator A5030586623 @default.
• W2992603401 creator A5046355746 @default.
• W2992603401 creator A5069460216 @default.
• W2992603401 creator A5080536692 @default.
• W2992603401 creator A5081302342 @default.
• W2992603401 creator A5091279323 @default.
• W2992603401 date "2019-12-01" @default.
• W2992603401 modified "2023-09-26" @default.
• W2992603401 title "Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome" @default.
• W2992603401 cites W2016552170 @default.
• W2992603401 cites W2045009458 @default.
• W2992603401 cites W2051838890 @default.
• W2992603401 cites W2107602422 @default.
• W2992603401 cites W2125616358 @default.
• W2992603401 cites W2157466346 @default.
• W2992603401 cites W2337659275 @default.
• W2992603401 cites W2346846664 @default.
• W2992603401 cites W2412725897 @default.
• W2992603401 cites W2586126825 @default.
• W2992603401 cites W2594496276 @default.
• W2992603401 cites W2605065173 @default.
• W2992603401 cites W2609973112 @default.
• W2992603401 cites W2611116831 @default.
• W2992603401 cites W2611189127 @default.
• W2992603401 cites W2612422239 @default.
• W2992603401 cites W2733520933 @default.
• W2992603401 cites W2805602843 @default.
• W2992603401 cites W2805968856 @default.
• W2992603401 cites W2890693336 @default.
• W2992603401 cites W2965827886 @default.
• W2992603401 doi "https://doi.org/10.1186/s40425-019-0801-z" @default.
• W2992603401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6894240" @default.
• W2992603401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31801591" @default.
• W2992603401 hasPublicationYear "2019" @default.
• W2992603401 type Work @default.
• W2992603401 sameAs 2992603401 @default.
• W2992603401 citedByCount "5" @default.
• W2992603401 countsByYear W29926034012020 @default.
• W2992603401 countsByYear W29926034012021 @default.
• W2992603401 countsByYear W29926034012022 @default.
• W2992603401 countsByYear W29926034012023 @default.
• W2992603401 crossrefType "journal-article" @default.
• W2992603401 hasAuthorship W2992603401A5003894390 @default.
• W2992603401 hasAuthorship W2992603401A5030586623 @default.
• W2992603401 hasAuthorship W2992603401A5046355746 @default.
• W2992603401 hasAuthorship W2992603401A5069460216 @default.
• W2992603401 hasAuthorship W2992603401A5080536692 @default.
• W2992603401 hasAuthorship W2992603401A5081302342 @default.
• W2992603401 hasAuthorship W2992603401A5091279323 @default.
• W2992603401 hasBestOaLocation W29926034011 @default.
• W2992603401 hasConcept C126322002 @default.
• W2992603401 hasConcept C143998085 @default.
• W2992603401 hasConcept C16005928 @default.
• W2992603401 hasConcept C203014093 @default.
• W2992603401 hasConcept C2776780870 @default.
• W2992603401 hasConcept C2777408962 @default.
• W2992603401 hasConcept C2777546739 @default.
• W2992603401 hasConcept C2777701055 @default.
• W2992603401 hasConcept C2777756187 @default.
• W2992603401 hasConcept C2778342957 @default.
• W2992603401 hasConcept C2779338263 @default.
• W2992603401 hasConcept C2779972918 @default.
• W2992603401 hasConcept C2780057760 @default.
• W2992603401 hasConcept C2780851360 @default.
• W2992603401 hasConcept C2781274730 @default.
• W2992603401 hasConcept C2911091166 @default.
• W2992603401 hasConcept C71924100 @default.
• W2992603401 hasConcept C8891405 @default.
• W2992603401 hasConceptScore W2992603401C126322002 @default.
• W2992603401 hasConceptScore W2992603401C143998085 @default.
• W2992603401 hasConceptScore W2992603401C16005928 @default.
• W2992603401 hasConceptScore W2992603401C203014093 @default.
• W2992603401 hasConceptScore W2992603401C2776780870 @default.
• W2992603401 hasConceptScore W2992603401C2777408962 @default.
• W2992603401 hasConceptScore W2992603401C2777546739 @default.
• W2992603401 hasConceptScore W2992603401C2777701055 @default.
• W2992603401 hasConceptScore W2992603401C2777756187 @default.
• W2992603401 hasConceptScore W2992603401C2778342957 @default.
• W2992603401 hasConceptScore W2992603401C2779338263 @default.
• W2992603401 hasConceptScore W2992603401C2779972918 @default.
• W2992603401 hasConceptScore W2992603401C2780057760 @default.
• W2992603401 hasConceptScore W2992603401C2780851360 @default.
• W2992603401 hasConceptScore W2992603401C2781274730 @default.
• W2992603401 hasConceptScore W2992603401C2911091166 @default.
• W2992603401 hasConceptScore W2992603401C71924100 @default.
• W2992603401 hasConceptScore W2992603401C8891405 @default.
• W2992603401 hasIssue "1" @default.
• W2992603401 hasLocation W29926034011 @default.
• W2992603401 hasLocation W29926034012 @default.
• W2992603401 hasLocation W29926034013 @default.
• W2992603401 hasLocation W29926034014 @default.
• W2992603401 hasLocation W29926034015 @default.
• W2992603401 hasOpenAccess W2992603401 @default.
• W2992603401 hasPrimaryLocation W29926034011 @default.
• W2992603401 hasRelatedWork W2366180244 @default.
• W2992603401 hasRelatedWork W2412678480 @default.
• W2992603401 hasRelatedWork W2440918980 @default.

• next